MedTrace Logo

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

NCT02500849 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-10-09

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

Conditions

Interventions

GENETIC

SB-728mR-HSPC Infusion 3 days following busulfan conditioning

Sponsors & Collaborators

  • Sangamo Therapeutics

    collaborator INDUSTRY

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Amrita Y. Krishnan, MD · City of Hope Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-10
Primary Completion
2026-08-24
Completion
2026-08-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500849 on ClinicalTrials.gov